BGC-0228

Primary objective: To determine the maximum tolerated dose (MTD) or Phase II recommended dose (RP2D) and safety of BGC0228 for injection in patients with advanced solid tumors who have failed standard treatment (disease progression or intolerance) or lack standard treatment. Secondary objective: To explore the pharmacokinetic (PK) characteristics of BGC0228 for injection monotherapy in patients with advanced solid tumors under single and multiple dosing conditions; to preliminarily evaluate the clinical efficacy of BGC0228 for injection monotherapy in patients with advanced solid tumors (such as pancreatic cancer, colorectal cancer, ovarian cancer, gastric cancer, esophageal cancer, breast cancer, non-small/small cell lung cancer, etc.).